Veracyte, Inc. filed a Form 8-K on November 4, 2026, disclosing the commencement of a Board-authorized share repurchase program and announcing financial results for the quarter ended September 30, 2026.

Key Highlights

  • Repurchase Program Size: The Board of Directors authorized repurchases of up to $100.0 million of Veracyte's outstanding common stock.
  • Program Duration: The repurchase program runs for a one-year period beginning on the date of the public announcement, according to the filing.
  • Repurchase Methods: Repurchases may be made via open-market transactions, Rule 10b5-1 trading plans, privately negotiated transactions, accelerated share repurchase transactions, or other transactions permitted by applicable law.
  • No Obligation to Repurchase: The filing states the program "does not obligate the Company to repurchase any specific number of shares" and may be modified, suspended, or discontinued at any time without prior notice.
  • Quarterly Results Also Announced: A press release covering financial results for the quarter ended September 30, 2026, was furnished as Exhibit 99.1 to the filing.
  • Signed By: The filing was signed by Rebecca Chambers, Chief Financial Officer and Principal Financial Officer.

Veracyte Announces $100 Million Buyback and Q3 2026 Financial Results

Veracyte, Inc. (NASDAQ:VCYT) filed a Current Report on Form 8-K dated November 4, 2026, covering two separate disclosures. Under Item 8.01, the company disclosed the commencement of a share repurchase program previously authorized by its Board of Directors. The program permits the company to repurchase up to $100.0 million of its outstanding common stock over a one-year period beginning on the date of public announcement.

According to the filing, repurchases under the program may be executed through open-market transactions, including those conducted in accordance with Rule 10b-18, trading plans adopted under Rule 10b5-1, privately negotiated transactions, accelerated share repurchase transactions, or other transactions, each in accordance with applicable laws and regulations. The filing states that "the timing, amount and terms of any repurchases will depend on a variety of factors," including market conditions, the trading price of the company's common stock, financial position and results of operations, capital requirements, and general business conditions.

The company also noted under Item 2.02 that it issued a press release on November 4, 2026, announcing its financial results for the quarter ended September 30, 2026. That press release was furnished as Exhibit 99.1 and, per the filing, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The filing was signed by Rebecca Chambers in her capacity as Chief Financial Officer and Principal Financial Officer.

What Was Disclosed

Veracyte's November 4, 2026 Form 8-K disclosed the launch of a $100.0 million share repurchase program authorized by its Board, along with the furnishing of a press release covering third-quarter 2026 financial results.